Cargando…

Editorial: Antibody Fc Engineering: Towards Better Therapeutics

Detalles Bibliográficos
Autores principales:	Lei, Cheng, Gong, Rui, Ying, Tianlei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208127/ https://www.ncbi.nlm.nih.gov/pubmed/30405636 http://dx.doi.org/10.3389/fimmu.2018.02450

Ejemplares similares

Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
por: Yang, Chunpeng, et al.
Publicado: (2018)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding
por: Wang, Chunyu, et al.
Publicado: (2017)

Single-Domain Antibodies As Therapeutics against Human Viral Diseases
por: Wu, Yanling, et al.
Publicado: (2017)

Interactions of IgG1 CH2 and CH3 Domains with FcRn
por: Ying, Tianlei, et al.
Publicado: (2014)

Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
por: Elter, Adrian, et al.
Publicado: (2021)

Editorial: Roles of Fc Receptors in Disease and Therapy
por: Ganesan, Latha P., et al.
Publicado: (2020)

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
por: Ha, Ji-Hee, et al.
Publicado: (2016)

Editorial: Understanding and Engineering Antibody-Superantigen Interactions
por: Gan, Samuel Ken-En, et al.
Publicado: (2022)

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa(V158) Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
por: Kang, Tae Hyun, et al.
Publicado: (2019)

Editorial: Effector functions of therapeutic antibodies
por: Boross, Peter, et al.
Publicado: (2023)

Corrigendum: Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins
por: Ha, Ji-Hee, et al.
Publicado: (2017)

Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life
por: Saxena, Abhishek, et al.
Publicado: (2016)

TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance
por: Fu, Wenyan, et al.
Publicado: (2021)

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
por: Abdeldaim, Dalia T., et al.
Publicado: (2023)

Editorial: Antibody Therapeutics for the Treatment of Filoviral Infection
por: Murin, Charles D., et al.
Publicado: (2022)

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2022)

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
por: Kasturirangan, Srinath, et al.
Publicado: (2017)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Editorial: Single-Domain Antibodies—Biology, Engineering and Emerging Applications
por: Henry, Kevin A., et al.
Publicado: (2018)

Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease
por: Fitzpatrick, Elizabeth A., et al.
Publicado: (2020)

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2023)

Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?
por: Ravlić, Sanda, et al.
Publicado: (2022)

A general Fc engineering platform for the next generation of antibody therapeutics
por: Chen, Da, et al.
Publicado: (2021)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020)

Fc-engineered antibody therapeutics with improved efficacy against COVID-19
por: Yamin, Rachel, et al.
Publicado: (2021)

Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models
por: Schmaljohn, Alan L., et al.
Publicado: (2019)

Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
por: Bailey, Elizabeth M., et al.
Publicado: (2021)

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
por: Huang, Zhaoliang, et al.
Publicado: (2022)

HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids
por: Cox, Freek, et al.
Publicado: (2016)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg?
por: Kremer, Leonor, et al.
Publicado: (2018)

Regulation of Immune Responses by the Neonatal Fc Receptor and Its Therapeutic Implications
por: Rath, Timo, et al.
Publicado: (2015)

IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
por: Breedveld, Annelot, et al.
Publicado: (2019)

The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019)

Assessing the Heterogeneity of the Fc-Glycan of a Therapeutic Antibody Using an engineered FcγReceptor IIIa-Immobilized Column
por: Kiyoshi, Masato, et al.
Publicado: (2018)

FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
por: Caratelli, Sara, et al.
Publicado: (2017)

Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
por: Teige, Ingrid, et al.
Publicado: (2019)

Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization
por: Su, Bin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tj5npbc1g7c14ngj69kivegjau